HBHarald Braun

Harald Braun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Harald Braun has a total of 167 co-authors. Here are the top co-authors by number of shared publications:

  • Rudi Beyaert

    Center for Inflammation Research, Unit of Molecular Signal Transduction in Inflammation, VIB, Ghent, Belgium

    7 shared publications
  • Guntram Suske

    Institute of Molecular Biology and Tumor Research (IMT), Philipps-University of Marburg, Marburg, Germany

    6 shared publications
  • Hamida Hammad

    Laboratory of Immunoregulation and Mucosal Immunology, VIB-UGent Center for Inflammation Research, Ghent, Belgium

    4 shared publications
  • Bart N. Lambrecht

    VIB-UGent Center for Inflammation Research, Zwijnaarde, Ghent 9052, Belgium

    3 shared publications
  • Rudi Beyaert

    VIB-UGent Center for Inflammation Research , UGent Department for Biomedical Molecular Biology, Unit of Molecular Signal Transduction in Inflammation , Technologiepark 927 , 9052 Ghent , Belgium

    3 shared publications
  • Claus Bachert

    Upper Airways Research Laboratory, Department of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium

    2 shared publications

Latest Publications

  • Open Access

    ST2 as checkpoint target for colorectal cancer immunotherapy

    by Kevin Van der Jeught, Yifan Sun, Yuanzhang Fang, Zhuolong Zhou, Hua Jiang, Tao Yu, Jinfeng Yang, Malgorzata M. Kamocka, Ka Man So, Yujing Li, et al.

    Immune checkpoint blockade immunotherapy delivers promising clinical results in colorectal cancer (CRC). However, only a fraction of cancer patients develop durable responses. The tumor microenvironment (TME) negatively impacts tumor immunity and subsequently clinical outcomes. Therefore, there is a need to identify other checkpoint targets associated with the TME. Early-onset factors secreted by stromal cells as well as tumor cells often help recruit immune cells to the TME, among which are alarmins such as IL-33. The only known receptor for IL-33 is stimulation 2 (ST2). Here we demonstrated that high ST2 expression is associated with poor survival and is correlated with low CD8 + T cell cytotoxicity in CRC patients. ST2 is particularly expressed in tumor-associated macrophages (TAMs). In preclinical models of CRC, we demonstrated that ST2-expressing TAMs (ST2 + TAMs) were recruited into the tumor via CXCR3 expression and exacerbated the immunosuppressive TME; and that combination of ST2 depletion using ST2 -KO mice with anti–programmed death 1 treatment resulted in profound growth inhibition of CRC. Finally, using the IL-33trap fusion protein, we suppressed CRC tumor growth and decreased tumor-infiltrating ST2 + TAMs. Together, our findings suggest that ST2 could serve as a potential checkpoint target for CRC immunotherapy.


  • Open Access

    Stabilization of the TAK1 adaptor proteins TAB2 and TAB3 is critical for optimal NF‐κB activation

    by Harald Braun, Jens Staal

    TAB2 and TAB3 bind to K63‐linked polyubiquitin chains and recruit the critical kinase MAP3K7 (TAK1). The polyubiquitin‐recruited TAK1/TAB2/TAB3 complex comes in close proximity with the IKK (IKKα/IKKβ/IKKγ) complex, which is recruited to M1‐linked polyubiquitin chains via the IKKγ (NEMO) component. Together, the two complexes activate the NF‐κB family of transcription factors. NF‐κB transcription factors are critical mediators of pro‐inflammatory signals and must be tightly regulated at multiple levels. Recently, it was discovered that one such point of regulation occurs at the level of TAB2 and TAB3 protein stability by the deubiquitinase USP15. Comment on: https://doi.org/10.1111/febs.15202


  • Open Access

    Molecular mechanisms of IL-33–mediated stromal interactions in cancer metastasis

    by Patrik Andersson, Yunlong Yang, Kayoko Hosaka, Yin Zhang, Carina Fischer, Harald Braun, Shuzhen Liu, Guohua Yu, Shihai Liu, Rudi Beyaert, et al.

    Molecular mechanisms underlying the cancer stroma in metastasis need further exploration. Here, we discovered that cancer-associated fibroblasts (CAFs) produced high levels of IL-33 that acted on tumor-associated macrophages (TAMs), causing them to undergo the M1 to M2 transition. Genomic profiling of metastasis-related genes in the IL-33–stimulated TAMs showed a >200-fold increase of MMP9. Signaling analysis demonstrated the IL-33-ST2-NF-κB-MMP9-laminin pathway that governed tumor stroma–mediated metastasis. In mouse and human fibroblast-rich pancreatic cancers, genetic deletion of IL-33, ST2, or MMP9 markedly blocked metastasis. Pharmacological inhibition of NF-κB and MMP9 also blocked cancer metastasis. Deletion of IL-33, ST2, or MMP9 restored laminin, a key basement membrane component associated with tumor microvessels. Together, our data provide mechanistic insights on the IL-33-NF-κB-MMP9-laminin axis that mediates the CAF-TAM–committed cancer metastasis. Thus, targeting the CAF-TAM-vessel axis provides an outstanding therapeutic opportunity for cancer treatment.


  • Staphylococcus aureus Induces a Mucosal Type 2 Immune Response via Epithelial Cell–derived Cytokines

    by Feng Lan, Nan Zhang, Gabriele Holtappels, Natalie De Ruyck, Olga Krysko, Koen Van Crombruggen, Harald Braun, Sebastian L. Johnston, Nikos G. Papadopoulos, Luo Zhang, et al.

    Rationale: Chronic rhinosinusitis with nasal polyps is characterized by a T-helper cell type 2–skewed upper airway inflammation. Mucosal Staphylococcus aureus colonization is found in the majority of patients with nasal polyps. S. aureus is known to induce type 2 cytokine release via enterotoxins. Objectives: To investigate the impact of non–enterotoxin-producing S. aureus on type 2 cytokine release. Methods: TSLP (thymic stromal lymphopoietin), IL-33, and type 2 cytokines were assessed in a human mucosal tissue model upon S. aureus infection. Measurements and Main Results: S. aureus exposure increased the expression of IL-33, TSLP, IL-5, and IL-13 in nasal polyp tissue, accompanied by elevated expression levels of TSLP and IL-33 receptors, predominantly on CD3+ T cells. S. aureus infection led to the release of TSLP, but not IL-33, IL-5, or IL-13, from healthy inferior turbinate tissue. In contrast, S. epidermidis did not induce any epithelial cell–derived cytokines in nasal polyp or healthy tissue. S. aureus infection also increased the release of IL-33 and TSLP in BEAS-2B epithelial cells, accompanied by activation of NF-κB (nuclear factor κB) pathways. Incubation with CU-CPT22, a specific Toll-like receptor 2 antagonist, significantly reduced the S. aureus–induced release of TSLP and IL-33, and the activity of the NF-κB signal in BEAS-2B cells. Conclusions: This study demonstrates for the first time that S. aureus can directly induce epithelial cell–derived cytokine release via binding to Toll-like receptor 2, and may thereby propagate type 2 cytokine expression in nasal polyp tissue.


  • Open Access

    Structure–Activity Relationship in Monosaccharide-Based Toll-Like Receptor 4 (TLR4) Antagonists

    by Fabio Alessandro Facchini, Lenny Zaffaroni, Alberto Minotti, Silvia Rapisarda, Valentina Calabrese, Matilde Forcella, Paola Fusi, Cristina Airoldi, Carlotta Ciaramelli, Jean-Marc Billod, et al.

    The structure-activity relationship was investigated in a series of synthetic TLR4 antagonists formed by a glucosamine core linked to two phosphate esters and two linear carbon chains. Molecular modeling showed that the compounds with 10, 12 and 14 carbons chains are associated to higher stabilization of the TLR4/MD-2 antagonist conformation than in the case of the C16 variant. Binding experiments with human MD-2 showed that the C12 and C14 variants have higher affinity than C10, while the C16 variant did not interact with the protein. The molecules, with the exception of the C16 variant, inhibited the LPS-stimulated TLR4 signal in human and murine cells and the antagonist potency mirrored the MD-2 affinity calculated from in vitro binding experiments. FT-IR, NMR, and SAXS measurements suggested that the aggregation state in aqueous solution depends on fatty acid chains lengths and that this property can influence TLR4 activity in this series of compounds.


  • The IL-33/ST2 axis is crucial in type 2 airway responses induced by Staphylococcus aureus–derived serine protease–like protein D

    by Andrea R. Teufelberger, Maria Nordengrün, Harald Braun, Tania Maes, Katrien De Grove, Gabriele Holtappels, Clara O'BRien, Sharen Provoost, Hamida Hammad, Amanda Gonçalves, et al.


  • Dichotomous function of IL-33 in health and disease: From biology to clinical implications

    by Harald Braun, Inna S. Afonina, Christina Mueller, Rudi Beyaert


  • Open Access

    Structure and antagonism of the receptor complex mediated by human TSLP in allergy and asthma

    by Kenneth Verstraete, Frank Peelman, Harald Braun, Juan Lopez, Dries Van Rompaey, Ann Dansercoer, Isabel Vandenberghe, Kris Pauwels, Jan Tavernier, Bart N. Lambrecht, et al.

    The pro-inflammatory cytokine thymic stromal lymphopoietin (TSLP) is pivotal to the pathophysiology of widespread allergic diseases mediated by type 2 helper T cell (Th2) responses, including asthma and atopic dermatitis. The emergence of human TSLP as a clinical target against asthma calls for maximally harnessing its therapeutic potential via structural and mechanistic considerations. Here we employ an integrative experimental approach focusing on productive and antagonized TSLP complexes and free cytokine. We reveal how cognate receptor TSLPR allosterically activates TSLP to potentiate the recruitment of the shared interleukin 7 receptor α-chain (IL-7Rα) by leveraging the flexibility, conformational heterogeneity and electrostatics of the cytokine. We further show that the monoclonal antibody Tezepelumab partly exploits these principles to neutralize TSLP activity. Finally, we introduce a fusion protein comprising a tandem of the TSLPR and IL-7Rα extracellular domains, which harnesses the mechanistic intricacies of the TSLP-driven receptor complex to manifest high antagonistic potency.


  • Open Access

    The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages

    by Yunlong Yang, Patrik Andersson, Kayoko Hosaka, Yin Zhang, Renhai Cao, Hideki Iwamoto, Xiaojuan Yang, Masaki Nakamura, Jian Wang, Rujie Zhuang, et al.

    Signalling molecules and pathways that mediate crosstalk between various tumour cellular compartments in cancer metastasis remain largely unknown. We report a mechanism of the interaction between perivascular cells and tumour-associated macrophages (TAMs) in promoting metastasis through the IL-33–ST2-dependent pathway in xenograft mouse models of cancer. IL-33 is the highest upregulated gene through activation of SOX7 transcription factor in PDGF-BB-stimulated pericytes. Gain- and loss-of-function experiments validate that IL-33 promotes metastasis through recruitment of TAMs. Pharmacological inhibition of the IL-33–ST2 signalling by a soluble ST2 significantly inhibits TAMs and metastasis. Genetic deletion of host IL-33 in mice also blocks PDGF-BB-induced TAM recruitment and metastasis. These findings shed light on the role of tumour stroma in promoting metastasis and have therapeutic implications for cancer therapy.


  • Interleukin-21-Producing CD4+ T Cells Promote Type 2 Immunity to House Dust Mites

    by Jonathan M. Coquet, Martijn J. Schuijs, Mark J. Smyth, Kim Deswarte, Rudi Beyaert, Harald Braun, Louis Boon, Gunilla B. Karlsson Hedestam, Steven L. Nutt, Hamida Hammad, et al.